We are live on
!
Find out more
KCM
Kynam Capital Management Portfolio holdings
AUM
$1.62B
1-Year Est. Return
138.67%
This Fund
S&P 500
This Quarter
Est. Return
+7.48%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$775M
AUM Growth
+$123M
(+19%)
Cap. Flow
+$132M
Cap. Flow
% of AUM
17.1%
Top 10 Holdings %
Top 10 Hldgs %
77.34%
Holding
39
New
8
Increased
12
Reduced
14
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TSVT
2seventy bio
TSVT
|
+$42.7M |
| 2 |
Travere Therapeutics
TVTX
|
+$24.3M |
| 3 |
Vaxcyte
PCVX
|
+$21.8M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
+$16M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$16M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
United Therapeutics
UTHR
|
+$27.8M |
| 2 |
CNCE
Concert Pharmaceuticals, Inc.
CNCE
|
+$25.8M |
| 3 |
Viridian Therapeutics
VRDN
|
+$15.7M |
| 4 |
APLS
Apellis Pharmaceuticals
APLS
|
+$15.5M |
| 5 |
Celldex Therapeutics
CLDX
|
+$8.45M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Gossamer Bio
GOSS
$66.5M
| $1.89M | 0.24% |
1,502,866
-268,679
| -15% | -$514K |
|
27
PUT
argenx
ARGX
$57.4B
| $1.68M | 0.22% |
+4,500
| New | +$1.67M |
|
28
Rhythm Pharmaceuticals
RYTM
$7B
| $1.65M | 0.21% |
+92,602
| New | +$2.33M |
|
29
Puma Biotechnology
PBYI
$406M
| $1.46M | 0.19% |
473,070
-88,539
| -16% | -$334K |
|
30
Xenon Pharmaceuticals
XENE
$6.32B
| $1.03M | 0.13% |
28,696
-191
| -0.7% | -$7.06K |
|
|
ACLX
31
DELISTED
Arcellx
ACLX
| $965K | 0.12% |
+31,336
| New | +$951K |
|
|
CNTB
32
Connect Biopharma Holdings
CNTB
$135M
| $740K | 0.1% |
739,649
| – | – |
|
|
MRUS
33
DELISTED
Merus
MRUS
| $395K | 0.05% |
+21,457
| New | +$374K |
|
34
Neurogene
NGNE
$696M
| $84K | 0.01% |
5,998
-40
| -0.7% | -$469 |
|
35
Gyre Therapeutics
GYRE
$662M
| $18.6K | ﹤0.01% |
5,992
-6,073
| -50% | -$23.1K |
|
|
APLS
36
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-300,000
| Closed | -$15.5M |
|
37
Cabaletta Bio
CABA
$439M
| – | – |
-165,486
| Closed | -$1.53M |
|
|
38
United Therapeutics
UTHR
$26.3B
| – | – |
-100,000
| Closed | -$27.8M |
|
|
CNCE
39
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| – | – |
-4,420,349
| Closed | -$25.8M |
|
Similar funds
IPW
WIC
HH
TLFA
KCM
PRA
BW
CC
Kynam Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Kynam Capital Management held 39 positions worth $775M, up 19% from $652M the previous quarter. Its ten largest holdings account for 77% of the portfolio.
Kynam Capital Management deployed $132M of net new capital in Q1 2023, opening 8 new positions and adding to 12 existing holdings. Its largest new stake was 2seventy bio: 3,738,972 shares worth $38.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier.
On the sell side, the largest reduction was Viridian Therapeutics, an estimated $15.7M trimmed.
- Kynam Capital Management's largest Q1 2023 buy was 2seventy bio: 3,738,972 shares worth $38.1M.
- Kynam Capital Management added most to Travere Therapeutics in Q1 2023, an estimated $24.3M increase.
- Kynam Capital Management's biggest Q1 2023 reduction was Viridian Therapeutics, cutting an estimated $15.7M.
- Kynam Capital Management fully exited United Therapeutics in Q1 2023, selling an estimated $27.8M.
- Kynam Capital Management's ten largest holdings make up 77% of its $775M portfolio in Q1 2023.
- Kynam Capital Management opened 8 new positions and closed 4 in Q1 2023.
- Kynam Capital Management's portfolio value rose 19% quarter-over-quarter to $775M.
Based on Kynam Capital Management's 13F filing for Q1 2023, filed 15 May 2023.